Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-155-5p ABI2 0.71 0.00687 0.18 0.14787 mirMAP -0.23 0 NA
2 hsa-miR-155-5p ABL2 0.71 0.00687 0.82 0 mirMAP -0.11 1.0E-5 NA
3 hsa-miR-155-5p ACADSB 0.71 0.00687 -0.98 0 mirMAP -0.13 0.00018 NA
4 hsa-miR-155-5p ACTA1 0.71 0.00687 -0.34 0.3688 MirTarget; miRNATAP -0.45 0 NA
5 hsa-miR-155-5p ACVR2A 0.71 0.00687 -0.41 0.00039 miRNATAP -0.15 0 NA
6 hsa-miR-155-5p ADH5 0.71 0.00687 -0.37 0.00013 miRNAWalker2 validate -0.1 0 NA
7 hsa-miR-155-5p AGL 0.71 0.00687 -0.17 0.16618 miRNAWalker2 validate -0.13 1.0E-5 NA
8 hsa-miR-155-5p AGTR1 0.71 0.00687 -2.47 0 miRNAWalker2 validate; miRTarBase -0.76 0 22525818 MicroRNA-155 miR-155 is one of the micro RNAs miRNA most consistently involved in neoplastic diseases and it is known to repress the angiotensin II type 1 receptor AGTR1; The aim of the present study was to evaluate the expressions of miR-155 and AGTR1 and to clarify the potential efficacy of anti-miR-155 alone and in combination with AGTR1 blocker losartan in endometrial cancers; Expressions of miR-155 and AGTR1 were evaluated using real-time PCR and immunohistochemistry; miR-155 was over-expressed and AGTR1 was underexpressed in endometrial carcinoma tissues; We checked that abolishing the function of miR-155 and AGTR1 by anti-miR-155 or losartan inhibited cell survival of endometrial carcinoma cells respectively and furthermore combined treatment showed synergistic effects; In this study we characterized the expressions of miR-155 and AGTR1 in endometrial tissues; The combined treatment with anti-miR-155 and losartan has a synergistic antiproliferative effect and an improved understanding is required to clarify whether miR-155 and AGTR1 can be used as a novel therapeutic target in endometrial cancer
9 hsa-miR-155-5p ALDH1A2 0.71 0.00687 -2.41 0 miRNAWalker2 validate -0.47 0 NA
10 hsa-miR-155-5p AMIGO2 0.71 0.00687 0.61 0.01903 miRNAWalker2 validate -0.2 0.00101 NA
11 hsa-miR-155-5p ANAPC16 0.71 0.00687 -0.56 0 miRNAWalker2 validate -0.12 0 NA
12 hsa-miR-155-5p ANKH 0.71 0.00687 0.46 0.00392 mirMAP -0.16 1.0E-5 NA
13 hsa-miR-155-5p ANO5 0.71 0.00687 -2.17 0 MirTarget -0.64 0 NA
14 hsa-miR-155-5p ANTXR1 0.71 0.00687 0.82 0.00014 miRNAWalker2 validate -0.24 0 NA
15 hsa-miR-155-5p ANTXR2 0.71 0.00687 -0.73 0.00186 MirTarget; miRNATAP -0.33 0 NA
16 hsa-miR-155-5p AR 0.71 0.00687 -1.55 0 mirMAP -0.56 0 NA
17 hsa-miR-155-5p ARHGAP5 0.71 0.00687 -0.12 0.26304 mirMAP -0.18 0 NA
18 hsa-miR-155-5p ARL10 0.71 0.00687 -0.28 0.19832 miRNAWalker2 validate -0.31 0 NA
19 hsa-miR-155-5p ARL8B 0.71 0.00687 -0.21 0.01117 miRNAWalker2 validate -0.11 0 NA
20 hsa-miR-155-5p ARMC2 0.71 0.00687 0.21 0.09317 miRNAWalker2 validate -0.14 0 NA
21 hsa-miR-155-5p ATF7 0.71 0.00687 0.07 0.43806 mirMAP -0.15 0 NA
22 hsa-miR-155-5p ATL2 0.71 0.00687 -0.38 0.00058 miRNAWalker2 validate -0.21 0 NA
23 hsa-miR-155-5p ATRNL1 0.71 0.00687 -1.69 1.0E-5 MirTarget; mirMAP -0.57 0 NA
24 hsa-miR-155-5p AXL 0.71 0.00687 -0.19 0.3511 miRNAWalker2 validate -0.16 0.00064 NA
25 hsa-miR-155-5p BCL6 0.71 0.00687 -0.21 0.19489 miRNAWalker2 validate; miRTarBase -0.19 0 23169640 We show that Bcl6 is indirectly regulated by miR-155 through Mxd1/Mad1 up-regulation; Interestingly we found that miR-155 directly targets HDAC4 a corepressor partner of BCL6; Meta-analysis of the diffuse large B-cell lymphoma patient microarray data showed that miR-155 expression is inversely correlated with Bcl6 and Hdac4; Hence this study provides a better understanding of how miR-155 causes disruption of the BCL6 transcriptional machinery that leads to up-regulation of the survival and proliferation genes in miR-155-induced leukemias
26 hsa-miR-155-5p BCORL1 0.71 0.00687 0.35 0.01214 MirTarget -0.18 0 NA
27 hsa-miR-155-5p BNC2 0.71 0.00687 -0.49 0.09988 MirTarget -0.38 0 NA
28 hsa-miR-155-5p BNIP2 0.71 0.00687 -0.05 0.63907 mirMAP -0.16 0 NA
29 hsa-miR-155-5p BOC 0.71 0.00687 -0.91 0.0056 MirTarget -0.44 0 NA
30 hsa-miR-155-5p BRWD1 0.71 0.00687 0.05 0.6598 mirMAP -0.15 0 NA
31 hsa-miR-155-5p C3orf18 0.71 0.00687 -1.27 0 miRNATAP -0.28 0 NA
32 hsa-miR-155-5p CA5B 0.71 0.00687 -0.07 0.65344 mirMAP -0.21 0 NA
33 hsa-miR-155-5p CAB39L 0.71 0.00687 -1.77 0 miRNAWalker2 validate -0.55 0 NA
34 hsa-miR-155-5p CACNA2D1 0.71 0.00687 -0.85 0.00675 mirMAP -0.45 0 NA
35 hsa-miR-155-5p CACNB4 0.71 0.00687 -1.06 0.0002 mirMAP; miRNATAP -0.28 2.0E-5 NA
36 hsa-miR-155-5p CADM2 0.71 0.00687 -3.78 0 mirMAP -0.81 0 NA
37 hsa-miR-155-5p CALU 0.71 0.00687 0.67 0 miRNAWalker2 validate -0.1 6.0E-5 NA
38 hsa-miR-155-5p CAMTA1 0.71 0.00687 -0.44 1.0E-5 miRNAWalker2 validate; MirTarget -0.11 0 NA
39 hsa-miR-155-5p CBR4 0.71 0.00687 -0.32 0.00664 miRNAWalker2 validate -0.16 0 NA
40 hsa-miR-155-5p CBX5 0.71 0.00687 0.16 0.24446 mirMAP -0.15 0 NA
41 hsa-miR-155-5p CCDC82 0.71 0.00687 0.34 0.00084 miRNAWalker2 validate -0.12 0 NA
42 hsa-miR-155-5p CD109 0.71 0.00687 0.26 0.3195 miRNAWalker2 validate -0.38 0 NA
43 hsa-miR-155-5p CDH13 0.71 0.00687 0.63 0.00094 miRNAWalker2 validate -0.22 0 NA
44 hsa-miR-155-5p CDH2 0.71 0.00687 -0.68 0.04042 miRNAWalker2 validate -0.3 7.0E-5 NA
45 hsa-miR-155-5p CDH6 0.71 0.00687 0.84 0 miRNAWalker2 validate -0.21 0 NA
46 hsa-miR-155-5p CELF2 0.71 0.00687 -1.1 1.0E-5 miRNATAP -0.12 0.04671 NA
47 hsa-miR-155-5p CEP68 0.71 0.00687 -0.36 0.00246 MirTarget -0.22 0 NA
48 hsa-miR-155-5p CFL2 0.71 0.00687 -1.3 0 miRNAWalker2 validate -0.51 0 NA
49 hsa-miR-155-5p CHD9 0.71 0.00687 -0.26 0.02092 miRNAWalker2 validate -0.13 0 NA
50 hsa-miR-155-5p CHST9 0.71 0.00687 -3.2 0 miRNATAP -0.67 0 NA
51 hsa-miR-155-5p CLIC4 0.71 0.00687 -0.39 0.04124 miRNAWalker2 validate -0.33 0 NA
52 hsa-miR-155-5p CNTN3 0.71 0.00687 -2.46 0 MirTarget -0.44 1.0E-5 NA
53 hsa-miR-155-5p CNTN4 0.71 0.00687 -0.83 0.00133 miRNATAP -0.27 1.0E-5 NA
54 hsa-miR-155-5p COL4A2 0.71 0.00687 1.02 0 miRNAWalker2 validate -0.2 1.0E-5 NA
55 hsa-miR-155-5p CPEB4 0.71 0.00687 -0.8 0 mirMAP -0.17 0 NA
56 hsa-miR-155-5p CRAT 0.71 0.00687 -0.93 1.0E-5 miRNAWalker2 validate -0.15 0.00135 NA
57 hsa-miR-155-5p CREBRF 0.71 0.00687 -0.37 0.00727 miRNAWalker2 validate; MirTarget; miRNATAP -0.19 0 NA
58 hsa-miR-155-5p CUL4B 0.71 0.00687 0.16 0.10357 miRNAWalker2 validate -0.14 0 NA
59 hsa-miR-155-5p CUX1 0.71 0.00687 -0.04 0.6705 miRNAWalker2 validate -0.11 0 NA
60 hsa-miR-155-5p CYP2U1 0.71 0.00687 -0.7 0.00028 miRNAWalker2 validate -0.22 0 NA
61 hsa-miR-155-5p CYR61 0.71 0.00687 -0.31 0.22652 miRNAWalker2 validate; miRTarBase -0.15 0.01455 NA
62 hsa-miR-155-5p DACH2 0.71 0.00687 -1.63 0.00034 mirMAP -0.39 0.00024 NA
63 hsa-miR-155-5p DBN1 0.71 0.00687 -0.23 0.22787 miRNAWalker2 validate -0.22 0 NA
64 hsa-miR-155-5p DCAF10 0.71 0.00687 -0.03 0.75108 mirMAP -0.12 0 NA
65 hsa-miR-155-5p DCUN1D2 0.71 0.00687 0.17 0.12271 miRNAWalker2 validate -0.18 0 NA
66 hsa-miR-155-5p DCUN1D4 0.71 0.00687 -0.26 0.02159 miRNATAP -0.19 0 NA
67 hsa-miR-155-5p DGKG 0.71 0.00687 -1.63 0 mirMAP -0.46 0 NA
68 hsa-miR-155-5p DIXDC1 0.71 0.00687 -1.16 0 MirTarget -0.48 0 NA
69 hsa-miR-155-5p DMD 0.71 0.00687 -1.51 0 miRNAWalker2 validate -0.66 0 NA
70 hsa-miR-155-5p DOCK4 0.71 0.00687 0.5 0.00108 miRNAWalker2 validate -0.11 0.00163 NA
71 hsa-miR-155-5p DPP8 0.71 0.00687 -0.01 0.89537 mirMAP -0.11 0 NA
72 hsa-miR-155-5p DYNC1I1 0.71 0.00687 -1.12 0.00107 MirTarget; miRNATAP -0.64 0 NA
73 hsa-miR-155-5p DYNC2H1 0.71 0.00687 -0.56 0.01731 miRNAWalker2 validate -0.39 0 NA
74 hsa-miR-155-5p EBF1 0.71 0.00687 -0.38 0.08856 miRNATAP -0.17 0.00122 NA
75 hsa-miR-155-5p EBF2 0.71 0.00687 1.63 0 mirMAP -0.46 0 NA
76 hsa-miR-155-5p EBF3 0.71 0.00687 -0.06 0.81437 mirMAP -0.23 4.0E-5 NA
77 hsa-miR-155-5p EEF1A2 0.71 0.00687 -3.58 0 miRNAWalker2 validate -0.47 0.00052 NA
78 hsa-miR-155-5p EGFR 0.71 0.00687 -0.17 0.48451 miRNAWalker2 validate; MirTarget -0.14 0.01476 NA
79 hsa-miR-155-5p EIF4E3 0.71 0.00687 -1.24 0 mirMAP -0.2 0 NA
80 hsa-miR-155-5p ENTPD3 0.71 0.00687 -2.57 0 MirTarget -0.48 0 NA
81 hsa-miR-155-5p EPHA5 0.71 0.00687 -0.96 0.01733 mirMAP -0.53 0 NA
82 hsa-miR-155-5p ERBB4 0.71 0.00687 -1.97 2.0E-5 mirMAP -0.44 4.0E-5 NA
83 hsa-miR-155-5p ETNK2 0.71 0.00687 -0.69 0.03013 miRNATAP -0.49 0 NA
84 hsa-miR-155-5p ETV1 0.71 0.00687 -0.1 0.67674 mirMAP -0.33 0 NA
85 hsa-miR-155-5p FADS1 0.71 0.00687 0.27 0.2134 miRNAWalker2 validate -0.18 0.00028 NA
86 hsa-miR-155-5p FAM114A1 0.71 0.00687 -0.46 0.0001 mirMAP -0.1 0.00014 NA
87 hsa-miR-155-5p FAM168A 0.71 0.00687 -0.19 0.12893 MirTarget -0.13 1.0E-5 NA
88 hsa-miR-155-5p FAM20B 0.71 0.00687 0.01 0.91599 mirMAP -0.22 0 NA
89 hsa-miR-155-5p FAM212B 0.71 0.00687 -1 0 MirTarget; miRNATAP -0.34 0 NA
90 hsa-miR-155-5p FAM8A1 0.71 0.00687 -0.22 0.02652 mirMAP -0.16 0 NA
91 hsa-miR-155-5p FBXL2 0.71 0.00687 -0.04 0.8586 MirTarget -0.39 0 NA
92 hsa-miR-155-5p FGF2 0.71 0.00687 -1.03 2.0E-5 miRNAWalker2 validate; mirMAP -0.38 0 NA
93 hsa-miR-155-5p FGF5 0.71 0.00687 0.55 0.28659 mirMAP -0.74 0 NA
94 hsa-miR-155-5p FGF7 0.71 0.00687 -0.41 0.18581 miRNAWalker2 validate; miRTarBase; mirMAP; miRNATAP -0.33 1.0E-5 NA
95 hsa-miR-155-5p FGF9 0.71 0.00687 -0.57 0.17095 miRNATAP -0.32 0.00074 NA
96 hsa-miR-155-5p FIGN 0.71 0.00687 -0.9 0.00585 mirMAP -0.28 0.00024 NA
97 hsa-miR-155-5p FKBP14 0.71 0.00687 0.49 8.0E-5 mirMAP -0.17 0 NA
98 hsa-miR-155-5p FKBP5 0.71 0.00687 -0.94 1.0E-5 mirMAP -0.13 0.00864 NA
99 hsa-miR-155-5p FLNA 0.71 0.00687 -0.77 0.01377 miRNAWalker2 validate -0.52 0 NA
100 hsa-miR-155-5p FLRT2 0.71 0.00687 -0.05 0.86608 mirMAP -0.22 0.0013 NA
101 hsa-miR-155-5p FMO2 0.71 0.00687 -0.97 0.01987 mirMAP -0.21 0.03467 NA
102 hsa-miR-155-5p FOXK1 0.71 0.00687 0.73 0 miRNAWalker2 validate; miRNATAP -0.13 5.0E-5 NA
103 hsa-miR-155-5p FOXO3 0.71 0.00687 -0.04 0.72028 miRNAWalker2 validate; miRTarBase -0.15 0 27596294; 25480585; 20371610; 26398931; 22027557; 27107135 MiR-155 targets 3´UTR region of multiple components of the pro-oncogenic signaling cascades including FOXO3a tumor suppressor and RUNX2 transcription factor regulating metastatic potential in BC;The effect of miRNA155 on FOXO3a expression was examined by Western blotting; FOXO3a was found to be a possible target of miRNA155 as suggested by Targetscan website;MicroRNA 155 regulates cell survival growth and chemosensitivity by targeting FOXO3a in breast cancer; In this study we demonstrate the critical role of miR-155 in regulation of cell survival and chemosensitivity through down-regulation of FOXO3a in breast cancer; Further we identified FOXO3a as a direct target of miR-155; Sustained overexpression of miR-155 resulted in repression of FOXO3a protein without changing mRNA levels and knockdown of miR-155 increases FOXO3a; Finally inverse correlation between miR-155 and FOXO3a levels were observed in a panel of breast cancer cell lines and tumors; In conclusion our study reveals a molecular link between miR-155 and FOXO3a and presents evidence that miR-155 is a critical therapeutic target in breast cancer;In contrast downregulation of miR-155-5p increased sensitivity to bufalin and upregulated the expression of FOXO3A;Here we show that hypoxic conditions induce miR-155 expression in lung cancer cells and trigger a corresponding decrease in a validated target FOXO3A;Our results further revealed that forkhead box O3a FoxO3a was a miR-155 target in the heart; And miR-155 directly repressed FoxO3a whose expression was mitigated in miR-155 agomir and mimic treatment in vivo and in vitro
104 hsa-miR-155-5p FSTL1 0.71 0.00687 0.59 0.00382 miRNAWalker2 validate -0.22 0 NA
105 hsa-miR-155-5p FUBP3 0.71 0.00687 0.16 0.02317 miRNAWalker2 validate -0.11 0 NA
106 hsa-miR-155-5p FZD3 0.71 0.00687 0.1 0.60316 mirMAP -0.3 0 NA
107 hsa-miR-155-5p GABARAPL1 0.71 0.00687 -1.2 0 miRNAWalker2 validate -0.19 1.0E-5 NA
108 hsa-miR-155-5p GABRB2 0.71 0.00687 -1.84 0.00029 mirMAP -0.52 1.0E-5 NA
109 hsa-miR-155-5p GAPVD1 0.71 0.00687 0.2 0.02872 miRNAWalker2 validate -0.11 0 NA
110 hsa-miR-155-5p GCFC2 0.71 0.00687 0.27 0.0082 miRNAWalker2 validate -0.12 0 NA
111 hsa-miR-155-5p GFRA1 0.71 0.00687 -3.07 0 mirMAP -0.53 1.0E-5 NA
112 hsa-miR-155-5p GNB4 0.71 0.00687 -0.06 0.76083 miRNAWalker2 validate -0.19 5.0E-5 NA
113 hsa-miR-155-5p GPAM 0.71 0.00687 0.14 0.29732 miRNAWalker2 validate -0.16 0 NA
114 hsa-miR-155-5p GPM6B 0.71 0.00687 -2.16 0 miRNAWalker2 validate; MirTarget -0.57 0 NA
115 hsa-miR-155-5p GRIP1 0.71 0.00687 -0.82 0.0011 miRNATAP -0.35 0 NA
116 hsa-miR-155-5p GYG1 0.71 0.00687 -0.45 0.00051 MirTarget -0.18 0 NA
117 hsa-miR-155-5p HBP1 0.71 0.00687 -0.45 0 miRNAWalker2 validate; MirTarget; miRNATAP -0.11 0 25666090 miR 155 promotes the growth of osteosarcoma in a HBP1 dependent mechanism; HMG-box transcription factor 1 HBP1 a strong Wnt pathway suppressor was found to be a target of miR-155; Restoration of HBP1 abolished the effect of miR-155 on OS cells
118 hsa-miR-155-5p HECA 0.71 0.00687 -0.22 0.03463 MirTarget -0.13 0 NA
119 hsa-miR-155-5p HIVEP2 0.71 0.00687 -0 0.99823 miRNAWalker2 validate; miRTarBase; miRNATAP -0.16 0 NA
120 hsa-miR-155-5p HSDL1 0.71 0.00687 0.15 0.16056 miRNAWalker2 validate -0.14 0 NA
121 hsa-miR-155-5p HSPA4L 0.71 0.00687 -0.1 0.744 miRNAWalker2 validate -0.15 0.03154 NA
122 hsa-miR-155-5p HTRA1 0.71 0.00687 0.21 0.25867 miRNAWalker2 validate -0.15 0.00083 NA
123 hsa-miR-155-5p HUNK 0.71 0.00687 0.47 0.10393 mirMAP -0.19 0.00464 NA
124 hsa-miR-155-5p IGF1 0.71 0.00687 -0.2 0.5898 mirMAP -0.28 0.0012 NA
125 hsa-miR-155-5p IGF1R 0.71 0.00687 0.12 0.57112 mirMAP -0.13 0.00801 NA
126 hsa-miR-155-5p IL13RA1 0.71 0.00687 0.02 0.86949 miRNAWalker2 validate; miRTarBase -0.15 0 NA
127 hsa-miR-155-5p IL17RD 0.71 0.00687 -0.02 0.94873 mirMAP -0.63 0 NA
128 hsa-miR-155-5p IL6ST 0.71 0.00687 -0.4 0.00676 mirMAP -0.15 1.0E-5 NA
129 hsa-miR-155-5p IMPAD1 0.71 0.00687 0.29 0.0008 miRNAWalker2 validate -0.12 0 NA
130 hsa-miR-155-5p INA 0.71 0.00687 -2.51 0 miRNAWalker2 validate -0.5 0 NA
131 hsa-miR-155-5p INPP5F 0.71 0.00687 0.05 0.70327 miRNAWalker2 validate -0.2 0 NA
132 hsa-miR-155-5p IRF2BP2 0.71 0.00687 0.35 7.0E-5 MirTarget; miRNATAP -0.13 0 NA
133 hsa-miR-155-5p ITGB5 0.71 0.00687 0.36 0.00664 miRNAWalker2 validate -0.11 0.00016 NA
134 hsa-miR-155-5p JUN 0.71 0.00687 -0.93 0 miRNAWalker2 validate; miRTarBase -0.18 0 23693020 In the present study we demonstrated for the first time that activation of RAGE by S100P regulates oncogenic microRNA-155 miR-155 expression through Activator Protein-1 AP-1 stimulation in colon cancer cells
135 hsa-miR-155-5p KANK2 0.71 0.00687 -0.93 2.0E-5 miRNAWalker2 validate -0.43 0 NA
136 hsa-miR-155-5p KANSL1 0.71 0.00687 0.25 0.00277 miRNATAP -0.1 0 NA
137 hsa-miR-155-5p KANSL1L 0.71 0.00687 0.26 0.01018 MirTarget -0.13 0 NA
138 hsa-miR-155-5p KCNA1 0.71 0.00687 -2.36 0.00043 mirMAP; miRNATAP -0.77 0 NA
139 hsa-miR-155-5p KCND3 0.71 0.00687 -1.25 9.0E-5 mirMAP -0.22 0.00273 NA
140 hsa-miR-155-5p KDELC1 0.71 0.00687 0.95 0 miRNAWalker2 validate -0.1 0.00292 NA
141 hsa-miR-155-5p KDELC2 0.71 0.00687 0.22 0.08988 miRNAWalker2 validate -0.15 0 NA
142 hsa-miR-155-5p KDM3A 0.71 0.00687 0.13 0.22711 miRNAWalker2 validate; miRTarBase; miRNATAP -0.13 0 NA
143 hsa-miR-155-5p KDM5B 0.71 0.00687 0.27 0.01491 MirTarget -0.14 0 NA
144 hsa-miR-155-5p KIAA0430 0.71 0.00687 -0.3 0.00341 miRNAWalker2 validate -0.11 0 NA
145 hsa-miR-155-5p KIAA1462 0.71 0.00687 0.55 0.00405 MirTarget -0.11 0.01864 NA
146 hsa-miR-155-5p KIAA2022 0.71 0.00687 -2.81 0 mirMAP -0.72 0 NA
147 hsa-miR-155-5p KLHL5 0.71 0.00687 -0.05 0.79463 miRNAWalker2 validate -0.24 0 NA
148 hsa-miR-155-5p KPNA4 0.71 0.00687 0.14 0.13709 miRNATAP -0.14 0 NA
149 hsa-miR-155-5p LCA5 0.71 0.00687 0.34 0.04819 MirTarget -0.27 0 NA
150 hsa-miR-155-5p LDOC1 0.71 0.00687 -1.54 0 miRNAWalker2 validate; miRTarBase -0.3 0 NA
NumGOOverlapSizeP ValueAdj. P Value
1 CELL DEVELOPMENT 64 1426 1.264e-11 2.94e-08
2 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 74 1784 1.016e-11 2.94e-08
3 REGULATION OF CELL DIFFERENTIATION 65 1492 3.059e-11 4.744e-08
4 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 48 1004 8.52e-10 9.641e-07
5 CARDIOVASCULAR SYSTEM DEVELOPMENT 41 788 1.45e-09 9.641e-07
6 CIRCULATORY SYSTEM DEVELOPMENT 41 788 1.45e-09 9.641e-07
7 TISSUE DEVELOPMENT 62 1518 1.25e-09 9.641e-07
8 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 51 1142 2.459e-09 1.43e-06
9 INTRACELLULAR SIGNAL TRANSDUCTION 62 1572 4.811e-09 2.487e-06
10 NEUROGENESIS 57 1402 7.684e-09 3.575e-06
11 POSITIVE REGULATION OF GENE EXPRESSION 65 1733 1.36e-08 5.014e-06
12 REGULATION OF EPITHELIAL CELL PROLIFERATION 22 285 1.348e-08 5.014e-06
13 MUSCLE CELL DIFFERENTIATION 20 237 1.401e-08 5.014e-06
14 POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 16 154 2.197e-08 7.302e-06
15 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 45 1008 2.404e-08 7.457e-06
16 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 43 957 4.23e-08 1.206e-05
17 TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 36 724 4.926e-08 1.206e-05
18 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 62 1672 4.765e-08 1.206e-05
19 POSITIVE REGULATION OF CELL DIFFERENTIATION 39 823 4.748e-08 1.206e-05
20 REGULATION OF CELL DEVELOPMENT 39 836 7.173e-08 1.669e-05
21 STRIATED MUSCLE CELL DIFFERENTIATION 16 173 1.133e-07 2.511e-05
22 EPITHELIUM DEVELOPMENT 41 945 2.286e-07 4.834e-05
23 HEAD DEVELOPMENT 34 709 2.766e-07 5.595e-05
24 MUSCLE STRUCTURE DEVELOPMENT 25 432 3.886e-07 7.534e-05
25 MUSCLE CELL DEVELOPMENT 13 128 6.05e-07 0.0001083
26 CENTRAL NERVOUS SYSTEM DEVELOPMENT 38 872 5.874e-07 0.0001083
27 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 62 1805 6.997e-07 0.0001206
28 ACTIN FILAMENT BASED PROCESS 25 450 8.245e-07 0.0001323
29 RESPONSE TO ENDOGENOUS STIMULUS 53 1450 8.148e-07 0.0001323
30 EMBRYO DEVELOPMENT 38 894 1.076e-06 0.0001669
31 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 32 689 1.259e-06 0.0001889
32 ORGAN MORPHOGENESIS 36 841 1.791e-06 0.0002525
33 VASCULATURE DEVELOPMENT 25 469 1.742e-06 0.0002525
34 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 33 740 2.066e-06 0.0002761
35 REGULATION OF CELL PROLIFERATION 53 1496 2.077e-06 0.0002761
36 FOREBRAIN DEVELOPMENT 21 357 2.602e-06 0.0003363
37 REGULATION OF NERVOUS SYSTEM DEVELOPMENT 33 750 2.755e-06 0.0003465
38 SKELETAL SYSTEM DEVELOPMENT 24 455 3.374e-06 0.0004131
39 POSITIVE REGULATION OF CELL PROLIFERATION 34 814 5.96e-06 0.0007111
40 RESPONSE TO GROWTH FACTOR 24 475 6.991e-06 0.0008133
41 PEPTIDYL TYROSINE MODIFICATION 14 186 8.079e-06 0.0009063
42 CELLULAR COMPONENT MORPHOGENESIS 36 900 8.181e-06 0.0009063
43 CELL PROJECTION ORGANIZATION 36 902 8.588e-06 0.0009293
44 TUBE DEVELOPMENT 26 552 1.008e-05 0.001066
45 NEURON DIFFERENTIATION 35 874 1.073e-05 0.00111
46 REGULATION OF ENDOTHELIAL CELL PROLIFERATION 10 98 1.164e-05 0.001177
47 DEVELOPMENTAL GROWTH 19 333 1.203e-05 0.001191
48 HEART DEVELOPMENT 23 466 1.581e-05 0.001533
49 INOSITOL LIPID MEDIATED SIGNALING 11 124 1.642e-05 0.00156
50 NEGATIVE REGULATION OF GENE EXPRESSION 50 1493 1.926e-05 0.001766
51 POSITIVE REGULATION OF CELL DEVELOPMENT 23 472 1.936e-05 0.001766
52 GROWTH 21 410 2.151e-05 0.001888
53 POSITIVE REGULATION OF OSSIFICATION 9 84 2.15e-05 0.001888
54 PROTEIN PHOSPHORYLATION 36 944 2.283e-05 0.001967
55 MYOFIBRIL ASSEMBLY 7 48 2.377e-05 0.002011
56 SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 19 352 2.6e-05 0.00216
57 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 25 554 3.049e-05 0.002489
58 LOCOMOTION 40 1114 3.104e-05 0.002491
59 MOVEMENT OF CELL OR SUBCELLULAR COMPONENT 44 1275 3.161e-05 0.002493
60 POST EMBRYONIC DEVELOPMENT 9 89 3.429e-05 0.002659
61 EMBRYONIC CAMERA TYPE EYE DEVELOPMENT 6 35 3.568e-05 0.002722
62 BLOOD VESSEL MORPHOGENESIS 19 364 4.103e-05 0.003079
63 CELL PROLIFERATION 28 672 4.24e-05 0.003131
64 MORPHOGENESIS OF AN EPITHELIUM 20 400 4.726e-05 0.003436
65 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 57 1848 5.011e-05 0.003587
66 NEGATIVE REGULATION OF CELL PROLIFERATION 27 643 5.104e-05 0.003598
67 REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION 8 73 5.244e-05 0.003642
68 POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 21 437 5.436e-05 0.003719
69 CONNECTIVE TISSUE DEVELOPMENT 13 194 5.735e-05 0.003867
70 NEGATIVE REGULATION OF CELL DEATH 33 872 5.882e-05 0.00391
71 NEURON DEVELOPMENT 28 687 6.218e-05 0.003968
72 REPRODUCTIVE SYSTEM DEVELOPMENT 20 408 6.217e-05 0.003968
73 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 46 1395 6.225e-05 0.003968
74 NEURON PROJECTION DEVELOPMENT 24 545 6.444e-05 0.004052
75 RESPONSE TO TRANSFORMING GROWTH FACTOR BETA 11 144 6.581e-05 0.004083
76 ACTOMYOSIN STRUCTURE ORGANIZATION 8 77 7.708e-05 0.004658
77 REGULATION OF BMP SIGNALING PATHWAY 8 77 7.708e-05 0.004658
78 CARTILAGE DEVELOPMENT 11 147 7.932e-05 0.004732
79 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 14 229 8.117e-05 0.004781
80 NEURON PROJECTION GUIDANCE 13 205 0.0001005 0.005846
81 REGULATION OF GTPASE ACTIVITY 27 673 0.0001092 0.006274
82 REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 13 207 0.0001108 0.006288
83 EPITHELIAL CELL DIFFERENTIATION 22 495 0.0001137 0.006373
84 TISSUE MORPHOGENESIS 23 533 0.0001234 0.006758
85 PHOSPHORYLATION 41 1228 0.0001232 0.006758
86 PALATE DEVELOPMENT 8 85 0.0001555 0.008412
87 MUSCLE TISSUE DEVELOPMENT 15 275 0.0001628 0.008708
88 SECOND MESSENGER MEDIATED SIGNALING 11 160 0.0001688 0.008825
89 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 58 1977 0.0001672 0.008825
90 COLUMNAR CUBOIDAL EPITHELIAL CELL DIFFERENTIATION 9 111 0.0001923 0.009626
91 MESENCHYME DEVELOPMENT 12 190 0.0001919 0.009626
92 GLIAL CELL DIFFERENTIATION 10 136 0.0001924 0.009626
93 LENS DEVELOPMENT IN CAMERA TYPE EYE 7 66 0.0001901 0.009626
NumGOOverlapSizeP ValueAdj. P Value
1 NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY 62 1199 6.236e-14 5.793e-11
2 RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING 42 629 3.341e-13 1.552e-10
3 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 25 226 5.49e-13 1.7e-10
4 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING 27 315 2.711e-11 6.296e-09
5 TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 27 328 6.834e-11 1.27e-08
6 REGULATORY REGION NUCLEIC ACID BINDING 43 818 4.053e-10 6.276e-08
7 DOUBLE STRANDED DNA BINDING 40 764 1.958e-09 2.598e-07
8 CORE PROMOTER PROXIMAL REGION DNA BINDING 25 371 2.1e-08 2.439e-06
9 SEQUENCE SPECIFIC DNA BINDING 45 1037 5.522e-08 5.7e-06
10 PROTEIN TYROSINE KINASE ACTIVITY 13 176 2.075e-05 0.001927
11 TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING 11 133 3.17e-05 0.002677
12 SMAD BINDING 8 72 4.743e-05 0.003637
13 CHROMATIN BINDING 21 435 5.09e-05 0.003637
14 TRANSCRIPTION FACTOR BINDING 23 524 9.598e-05 0.006369
15 FIBROBLAST GROWTH FACTOR RECEPTOR BINDING 5 28 0.0001335 0.00827
NumGOOverlapSizeP ValueAdj. P Value

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 13 139 1.555e-06 8.086e-05
2 MAPK_signaling_pathway_hsa04010 15 295 0.0003461 0.008999
3 PI3K_Akt_signaling_pathway_hsa04151 15 352 0.00206 0.03364
4 FoxO_signaling_pathway_hsa04068 8 132 0.002856 0.03364
5 Ras_signaling_pathway_hsa04014 11 232 0.003556 0.03364
6 TGF_beta_signaling_pathway_hsa04350 6 84 0.00425 0.03364
7 Rap1_signaling_pathway_hsa04015 10 206 0.004529 0.03364
8 Adherens_junction_hsa04520 5 72 0.009935 0.062
9 Focal_adhesion_hsa04510 9 199 0.01073 0.062
10 Regulation_of_actin_cytoskeleton_hsa04810 9 208 0.01401 0.07283
11 mTOR_signaling_pathway_hsa04150 7 151 0.0205 0.09691
12 Mitophagy_animal_hsa04137 4 65 0.0304 0.1317
13 Apelin_signaling_pathway_hsa04371 6 137 0.03906 0.1562
14 ECM_receptor_interaction_hsa04512 4 82 0.06208 0.2265
15 ErbB_signaling_pathway_hsa04012 4 85 0.06896 0.2265
16 AMPK_signaling_pathway_hsa04152 5 121 0.06971 0.2265
17 Oocyte_meiosis_hsa04114 5 124 0.07566 0.2314
18 Phospholipase_D_signaling_pathway_hsa04072 5 146 0.1272 0.3675
19 Hippo_signaling_pathway_hsa04390 5 154 0.1491 0.4081
20 Gap_junction_hsa04540 3 88 0.2147 0.5582
21 Calcium_signaling_pathway_hsa04020 5 182 0.2362 0.585
22 Phosphatidylinositol_signaling_system_hsa04070 3 99 0.2679 0.5934
23 HIF_1_signaling_pathway_hsa04066 3 100 0.2728 0.5934
24 Wnt_signaling_pathway_hsa04310 4 146 0.2739 0.5934
25 Phagosome_hsa04145 4 152 0.2982 0.6202
26 TNF_signaling_pathway_hsa04668 3 108 0.3124 0.6248
27 cGMP_PKG_signaling_pathway_hsa04022 4 163 0.3433 0.6511
28 p53_signaling_pathway_hsa04115 2 68 0.3506 0.6511
29 Cell_cycle_hsa04110 3 124 0.3916 0.6916
30 Autophagy_animal_hsa04140 3 128 0.4111 0.6916
31 Endocytosis_hsa04144 5 244 0.4555 0.7178
32 cAMP_signaling_pathway_hsa04024 4 198 0.4852 0.7303
33 Cell_adhesion_molecules_.CAMs._hsa04514 3 145 0.4915 0.7303
34 Cellular_senescence_hsa04218 3 160 0.5577 0.7804
35 Jak_STAT_signaling_pathway_hsa04630 3 162 0.5661 0.7804
36 Cytokine_cytokine_receptor_interaction_hsa04060 4 270 0.7251 0.9427
37 Tight_junction_hsa04530 2 170 0.8172 0.9979
38 Neuroactive_ligand_receptor_interaction_hsa04080 3 278 0.8831 1

Quest ID: 70a24427ba3eed3b69df0ca2dc0b574e